Who's speaking at this Webinar?
Giovanna De Filippi, PhD
Business Development Manager, EMEA Axion Biosystems
Steven Broadbent, PhD
Senior Scientist (Electrophysiology) and Product Specialist, Axol Bioscience Ltd
Advances in human-induced pluripotent stem cell (hiPSC) technology enables the generation of donor-derived healthy and diseased cell lines. This has greatly benefitted the study of human disease phenotypes that are difficult to reproduce in animal models.
Therefore, hiPSCs provide an attractive option for use in a number of applications including human disease modeling, drug screening, personalized medicine, cell-based therapy, and toxicity studies. However, hiPSC generation remains labor-intensive, expensive and technically challenging with the validation of correct function and pharmacology requiring a substantial investment in time, expertise and equipment.
Attend the webinars to discover how to:
- Reprogram donor cells to iPSCs
- Edit genes of interest
- Differentiate iPSCs to relevant subtypes
- Validate phenotypically relevant function and pharmacology
- Session 1: Generation and Functional Characterization of hiPSC-Derived Cardiomyocytes
Session 2: Generation and Functional Characterization of hiPSC-Derived Cortical and Sensory Neurons
During this webinar, we will discuss our hiPSC-derived cardiomyocytes and a custom service we provide for their electrophysiological characterization using microelectrode arrays (MEA). The focus is on the development of disease models and cardiotoxicity screening.